... Dec 08
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with Calquence (acalabrutinib) remained progression-free for a median of 22 months.... Dec 07
CALAVI did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure... Nov 12
Calquence demonstrated superior progression-free survival and favorable tolerability in both previously untreated and relapsed or refractory patients... Nov 09
Early-stage human trial data on a vaccine being developed by AstraZeneca and Oxford University will be published on July 20. ... Jul 17
-Advertisements-